A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT

A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT

(1) Background: Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) who are biologically at high risk for the development of loco–regional recurrences after postoperative radiotherapy (PORT) but at intermediate risk according to clinical risk factors may benefit from additio...

Full description

Bibliographic Details
Main Authors: Shivaprasad Patil, Annett Linge, Hannah Hiepe, Marianne Grosser, Fabian Lohaus, Volker Gudziol, Max Kemper, Alexander Nowak, Dominik Haim, Inge Tinhofer, Volker Budach, Maja Guberina, Martin Stuschke, Panagiotis Balermpas, Jens von der Grün, Henning Schäfer, Anca-Ligia Grosu, Amir Abdollahi, Jürgen Debus, Ute Ganswindt, Claus Belka, Steffi Pigorsch, Stephanie E. Combs, Simon Boeke, Daniel Zips, Korinna Jöhrens, Gustavo B. Baretton, Michael Baumann, Mechthild Krause, Steffen Löck, on behalf of the DKTK-ROG
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Cancers
Subjects:
head and neck squamous cell carcinoma
gene signature
postoperative radiotherapy
postoperative radiochemotherapy
propensity score matching
Online Access:https://www.mdpi.com/2072-6694/14/12/3031

Internet

https://www.mdpi.com/2072-6694/14/12/3031

Similar Items